Medarex, Inc. (NASDAQ: MEDX) announced that its wholly owned MDX-1100 met its primary endpoints for patients receiving methotrexate in a Phase II ‘proof of concept’ trial in patients with active rheumatoid arthritis. The trial indicated that three-times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks when compared to placebo. So far we have shares indicated 3% higher on the news.
Read the full story at BioHealthInvestor.com.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.